You are reading a supplement label and you find it: a line that says something like “Advanced Mitochondrial Complex 400mg” followed by a list of six ingredients. The label lists each ingredient by name but gives no individual doses. There is just the single combined weight of 400 milligrams for the entire blend. This is a proprietary blend, and it is one of the most significant red flags in the supplement industry. Understanding exactly why helps you make better purchasing decisions and removes the uncertainty that these labels are specifically designed to create.
The proprietary blend is not a neutral labeling choice. It is a strategic one. Manufacturers who use it gain something specific, and what they gain comes at a direct cost to you as the buyer. The more clearly you understand the asymmetry, the more clearly you can see past the “proprietary formula” branding language to the actual information problem it represents.
Contents
What a Proprietary Blend Actually Means on a Label
Under FDA regulations, supplement manufacturers are required to list all ingredients on the Supplement Facts panel. They are also required to disclose the total weight of any blend they choose to create. What they are not required to do is disclose how much of each ingredient within a blend is present. This regulatory gap is the basis for the proprietary blend structure.
The practical consequence is significant. A blend labeled “Cellular Energy Blend 400mg” containing CoQ10, PQQ, ALCAR, and R-lipoic acid tells you those four ingredients are present in some amount totaling 400 milligrams. It does not tell you whether each is at a useful dose. Given that ALCAR at a research-meaningful dose requires at least 500 milligrams on its own, a 400 milligram blend containing ALCAR alongside three other ingredients is definitionally underdosing all of them, but the label conceals this by confirming only that the ingredients are present.
The ingredients within a proprietary blend are typically listed in descending order by weight, which provides a small amount of information. If CoQ10 appears first and PQQ appears last in a 400 milligram blend, the blend contains more CoQ10 than PQQ by weight. But you still do not know whether CoQ10 is present at 200 milligrams or 395 milligrams, and whether PQQ is present at five milligrams or one milligram. Descending order tells you relative rank, not absolute amount.
Why Manufacturers Use Proprietary Blends
Supplement manufacturers offer two justifications for proprietary blends, and it is worth understanding both before evaluating how persuasive they are.
The first justification is competitive protection: disclosing exact formulation details allows competitors to copy the formula, eliminating the research investment behind it. This argument has more validity for genuinely novel formulas than for most products. In practice, most proprietary blends contain the same ingredients that appear across dozens of similar products without the dose transparency. Protecting a formula that is not meaningfully differentiated from competitors is not protecting innovation.
The second justification is that the specific synergistic ratios between ingredients are trade secrets worth protecting. This argument is occasionally valid, and there are formulas where the ratio between ingredients genuinely matters and represents real intellectual property. However, even in these cases, the range of doses can be disclosed in ways that provide buyers with meaningful information without revealing exact ratios. Stating that CoQ10 is present “at a research-aligned dose” while protecting the exact milligram amount is a different disclosure failure than providing no dose information at all.
The honest assessment is that proprietary blends serve manufacturers’ interests primarily in two situations: when the formula genuinely has competitive value worth protecting, which describes a minority of products, and when the formula contains ingredients at doses too low to be meaningful but the manufacturer wants the ability to list those ingredients on the label. The second situation is far more common in practice, and the proprietary blend structure is the mechanism that makes it possible. The broader guide to label reading on this site, the article on how to read a supplement label, covers how to evaluate the full label context when proprietary blends are present.
How Proprietary Blends Can Mask Underdosing
The most practically consequential problem with proprietary blends is that they make underdosing invisible. This is not a theoretical concern. It is the most common reason proprietary blends are used in practice, and understanding the math makes it concrete.
Consider a product claiming to support mitochondrial energy with a blend containing CoQ10, PQQ, ALCAR, R-lipoic acid, magnesium malate, and BioPerine listed under a single 300 milligram blend. Research-relevant doses for these six ingredients are approximately: CoQ10 (bioavailable form) 100mg, PQQ 20mg, ALCAR 500mg, R-lipoic acid 100mg, magnesium malate 100mg elemental, BioPerine 5mg. Combined, a fully dosed formula would contain something in the range of 825 milligrams to 1,000 milligrams of active ingredients. A 300 milligram blend containing all six cannot be fully dosed. Mathematically, it is impossible. Yet the label lists all six ingredients, and a buyer unfamiliar with dose requirements might reasonably assume they are getting a complete cellular energy formula.
What is most likely happening in a blend like this is that the cheapest ingredient, probably CoQ10 at standard crystalline form, occupies most of the 300 milligrams, with trace amounts of the other five ingredients added to justify their presence on the label. The product can truthfully state it contains CoQ10, PQQ, ALCAR, R-lipoic acid, magnesium, and BioPerine. It cannot truthfully claim to provide these ingredients at doses that match the research showing those ingredients to be effective, but the proprietary blend structure allows it to benefit from the association without making the specific claim that would require disclosure.
What Transparent Labeling Looks Like by Comparison
Transparent labeling, where every ingredient is listed with its specific form and individual dose on the Supplement Facts panel, gives buyers enough information to make a meaningful comparison. A label that reads “MicroActive CoQ10 (as coenzyme Q10 microencapsulated with beta-cyclodextrin) 100mg” and “BioPQQ (pyrroloquinoline quinone, as fermented source) 20mg” and “Acetyl L-Carnitine HCL 750mg” is telling you something specific and verifiable.
You can check those doses against the research. You can verify that the forms specified are what they claim to be. You can calculate whether the formula is making physiological sense given what you know about dose requirements. And if you find those doses in a product that also passes the third-party testing and manufacturing quality checks, you have reasonable grounds for confidence that the product delivers what it claims.
Transparent labeling also creates accountability. A manufacturer who states “BioPQQ 20mg” on the label and delivers only 2mg is potentially liable for misbranding. A manufacturer who lists “Mitochondrial Complex 300mg (containing PQQ)” and delivers 2mg of PQQ is in technical compliance as long as PQQ is genuinely present in some quantity. The proprietary blend structure provides plausible deniability that transparent labeling does not, which is precisely why it exists and precisely why it should be treated as a red flag rather than a neutral labeling choice.
When a Proprietary Blend Is Potentially Acceptable
Proprietary blends are not automatically fraudulent. There are circumstances where their use is more defensible and the buyer is accepting a smaller information cost than in most cases.
If the manufacturer has published clinical research specifically on the formula, including dose information in the research methodology, the proprietary blend on the label is less opaque because the research provides dose transparency that the label does not. A formula with published clinical trials is demonstrably different from one with marketing claims alone, and buyers can access the research to understand what was actually used in the trials.
If the manufacturer provides dose range information through other channels, such as their website or direct communication, and those ranges correspond to research-relevant amounts, the information gap is smaller than the label alone suggests. This still requires extra effort from the buyer to access information that should be on the label, but it is a less egregious information failure than complete dose opacity.
The baseline expectation, however, should be transparent labeling with specific forms and individual doses. Any deviation from that baseline requires a specific justification, and “we prefer not to disclose our formula” is not one that serves buyers’ interests. The guide to branded versus generic ingredients covers a related quality dimension: how the presence of named branded ingredients like BioPQQ or MicroActive CoQ10 on a label provides a floor of dose and quality verification that generic ingredient labeling does not.
A proprietary blend is not always evidence of fraud, but it is always evidence that the manufacturer has chosen not to give you the information needed to evaluate their product. When justification for that omission is not forthcoming, treating the blend as a red flag is the rational response.
